MOESM1 of Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer

Tong, Xuexia; Tanino, Ryosuke; Sun, Rong; Tsubata, Yukari; Okimoto, Tamio; Takechi, Mayumi; Isobe, Takeshi

doi:10.6084/m9.figshare.11308931.v1

12931_2019_1244_MOESM1_ESM.pdf (1.87 MB)

MOESM1 of Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer

journal contribution

posted on 2019-12-03, 04:42 authored by Xuexia Tong, Ryosuke Tanino, Rong Sun, Yukari Tsubata, Tamio Okimoto, Mayumi Takechi, Takeshi Isobe

Additional file 1: Figure S1. PC-9 and PC-9/PEM do not express FGFR1 or FGFR4 proteins. Figure S2 PD173074 sensitized PC-9/PEM to erlotinib but BLU-554 and nintedanib did not. Figure S3. Representative pictures and body weights of xenografts. Figure S4. Establishment of erlotinib-resistant NSCLC cell lines. Figure S5. Sequence alignment between PTK2 (Y407 to F729) and FGFR1 (Y463 to L819). Table S1. The sequences for primers used in RT- qPCR.